SCYNEXIS, Inc.
SCYNEXIS develops medicines for difficult-to-treat infections in the US. Its lead product candidate is Ibrexafungerp for invasive candidiasis and other fungal infections. It also develops SCY-247 to treat systemic fungal diseases. The company has agreements with GlaxoSmithKline, Merck Sharp & Dohme, Hansoh, R-Pharm, and CJSC for ibrexafungerp development. Formerly known as SCYNEXIS Chemistry & Automation, the company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Overview
Strengths
- Price to book ratio (0.49) is lower than the sector mean (733.70).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |